USPSTF Recommends Against Aspirin for Primary Cardiovascular Prevention in Older Adults
The US Preventive Services Task Force (USPSTF) recommends against initiating low-dose aspirin for primary prevention of cardiovascular disease in adults aged 60 years and older, citing insufficient evidence of net benefit and potential harms.
Februery 2023
Cannabis Use Linked to Higher Emergency Care and Hospitalization Rates
Cannabis users experience higher rates of emergency care visits and hospitalizations for respiratory and all-cause morbidity and mortality, underscoring the need for comprehensive healthcare interventions addressing cannabis-related health outcomes.
January 2023
Pharmacokinetic Insights into Ciprofloxacin Treatment for Complicated Urinary Tract Infection in Children
Serum and urinary pharmacokinetics of ciprofloxacin are documented in children with complicated urinary tract infection, providing valuable insights into drug dosing and optimization strategies for this patient population.
January 2023
Treatment of Antibiotic-Resistant Gram-Negative Infections: Focus on Key Pathogens
A comprehensive review focuses on the treatment of infections caused by antibiotic-resistant Gram-negative bacteria, including AmpC-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia, highlighting therapeutic challenges and strategies.
December 2022
Methenamine Hippurate for Preventing Recurrent Urinary Tract Infections in Women: An Antibiotic-Sparing Approach
Methenamine hippurate represents an alternative to prophylactic antibiotics for preventing recurrent urinary tract infections in women, providing an antibiotic-sparing strategy to mitigate the risk of antimicrobial resistance and adverse drug reactions.
November 2022
New Therapeutic Target in Atherosclerosis Control: Insights from Molecular Research
Argentine and Spanish scientists identify a new therapeutic target in the control of atherosclerosis, paving the way for the development of novel drugs targeting key molecular pathways implicated in cardiovascular disease progression.
November 2022
Methenamine for Preventing Recurrent Urinary Tract Infections in Women: An Alternative to Antibiotics
Methenamine hippurate emerges as a promising alternative to prophylactic antibiotics for the prevention of recurrent urinary tract infections in women, offering potential benefits in reducing antimicrobial resistance and adverse effects associated with antibiotic use.
November 2022
WHO Recommends Two Treatments for COVID-19: Baricitinib and Sotrovimab
The WHO recommends two new treatments, baricitinib and a monoclonal antibody drug sotrovimab, for the treatment of COVID-19, based on emerging evidence of their efficacy and safety in reducing disease severity and mortality.
August 2022
Global Impact of Antibiotic Resistance: Public Health Warning
Antibiotic resistance poses a significant global health threat, with an estimated 1.2 million deaths projected by 2029, underscoring the urgent need for coordinated action to combat antimicrobial resistance and preserve the effectiveness of existing antibiotics.
August 2022
